Macrocyclic and Other Non-Group 1 Gadolinium Contrast Agents Deposit Low Levels of Gadolinium in Brain and Bone Tissue: Preliminary Results From 9 Patients With Normal Renal Function.
about
Gadolinium-based contrast agent toxicity: a review of known and proposed mechanismsContribution of metals to brain MR signal intensity: review articles.T1 hyperintensity on brain imaging subsequent to gadolinium-based contrast agent administration: what do we know about intracranial gadolinium deposition?Biomedical Applications of Metal-Encapsulated Fullerene Nanoparticles.The presence of the gadolinium-based contrast agent depositions in the brain and symptoms of gadolinium neurotoxicity - A systematic review.Safety assessment of gadolinium-based contrast agents (GBCAs) requires consideration of long-term adverse effects in all human tissuesDistribution and clearance of retained gadolinium in the brain: differences between linear and macrocyclic gadolinium based contrast agents in a mouse model.Gadolinium retention in the body: what we know and what we can do.Pediatric Patients Demonstrate Progressive T1-Weighted Hyperintensity in the Dentate Nucleus following Multiple Doses of Gadolinium-Based Contrast Agent.Targeted Contrast Agent Specific to an Oncoprotein in Tumor Microenvironment with the Potential for Detection and Risk Stratification of Prostate Cancer with MRI.Retention of Gadolinium-Based Contrast Agents in Multiple Sclerosis: Retrospective Analysis of an 18-Year Longitudinal Study.Repeated intravenous administration of gadobutrol does not lead to increased signal intensity on unenhanced T1-weighted images-a voxel-based whole brain analysis.Click Chemistry in the Development of Contrast Agents for Magnetic Resonance Imaging.Gadolinium-based contrast agents: A comprehensive risk assessment.Gadolinium-based contrast agents in pediatric magnetic resonance imaging.Up to 52 administrations of macrocyclic ionic MR contrast agent are not associated with intracranial gadolinium deposition: Multifactorial analysis in 385 patients.Signal intensity change on unenhanced T1-weighted images in dentate nucleus and globus pallidus after multiple administrations of gadoxetate disodium: an intraindividual comparative study.Gadolinium based contrast agents in current practice: Risks of accumulation and toxicity in patients with normal renal function.Penetration and distribution of gadolinium-based contrast agents into the cerebrospinal fluid in healthy rats: a potential pathway of entry into the brain tissue.Gadobutrol in India-A Comprehensive Review of Safety and Efficacy.Hydration number: crucial role in nuclear magnetic relaxivity of Gd(III) chelate-based nanoparticles.Biological effects of MRI contrast agents: gadolinium retention, potential mechanisms and a role for phosphorus.Deep Brain Nuclei T1 Shortening after Gadobenate Dimeglumine in Children: Influence of Radiation and Chemotherapy.Gadolinium-based Contrast Media, Cerebrospinal Fluid and the Glymphatic System: Possible Mechanisms for the Deposition of Gadolinium in the Brain.Carotid Artery Wall Imaging: Perspective and Guidelines from the ASNR Vessel Wall Imaging Study Group and Expert Consensus Recommendations of the American Society of Neuroradiology.Gadolinium Accumulation in the Deep Cerebellar Nuclei and Globus Pallidus After Exposure to Linear but Not Macrocyclic Gadolinium-Based Contrast Agents in a Retrospective Pig Study With High Similarity to Clinical Conditions.Absence of clinical cerebellar syndrome after serial injections of more than 20 doses of gadoterate, a macrocyclic GBCA: a monocenter retrospective study.The Effects of Gadolinium-Based Contrast Agents on the Cerebellum: from Basic Research to Neurological Practice and from Pregnancy to Adulthood.Gadolinium retention after administration of contrast agents based on linear chelators and the recommendations of the European Medicines Agency.Gadolinium accumulation after contrast-enhanced magnetic resonance imaging: what rheumatologists should know.Reply to Lancelot et al.: 'Lack of evidence of a relationship between magnetic resonance signal intensity changes in the globus pallidus and dentate nucleus, and repeated administrations of gadoterate meglumine in children'.Gadolinium Chelate Safety in Pregnancy: Barely Detectable Gadolinium Levels in the Juvenile Nonhuman Primate after in Utero Exposure.Effectiveness of a high relaxivity contrast agent administered at half dose in dynamic susceptibility contrast MRI of brain gliomas.Distribution and chemical forms of gadolinium in the brain: a review.Brain relaxometry after macrocyclic Gd-based contrast agent.Gadolinium deposition in the brain: association with various GBCAs using a generalized additive model.Gadopentetate but not gadobutrol accumulates in the dentate nucleus of multiple sclerosis patients.Super-resolution intracranial quiescent interval slice-selective magnetic resonance angiography.Longitudinal Assessment of Dentate Nuclei Relaxometry during Massive Gadobutrol Exposure.Differences in gadolinium retention after repeated injections of macrocyclic MR contrast agents to rats.
P2860
Q26751073-575F8EC6-5962-45D6-8CF3-8B2D67A1E272Q31051153-4AB2CA81-7CF6-4E47-B147-30E5FC9C3338Q31132207-A77E9D23-E30B-4B55-B2C6-809E1E67BB49Q31151525-E02DF267-62D5-4767-8AA1-D98CA247D7D2Q31161095-40FE6334-BB25-46C7-B693-08488BC372BAQ33613096-AA14F6EA-8D77-455B-BF84-31A11764C163Q36085936-F122F374-DDF5-4DF9-BBD6-E60C61DA3D87Q36329191-64C86C5F-8290-4848-9446-059586B97D90Q37510442-83D0114C-7694-4AE8-81CF-318E8BFC2734Q38716380-6FD5A9E3-BA21-4C6C-86AF-7CCB181F6ABCQ38790916-7D84A98D-07C3-44E1-A88F-853F8EF41B98Q38910017-831C41BC-C186-4B8D-93F5-A0A5C06C13B4Q38982559-8E390922-67DE-4C6A-8EEF-29AB6F3FF224Q39022872-EF99022F-31E6-47C6-A097-6EB29B1F470BQ39242162-8D88FD50-79D8-40AB-A135-C4207300E444Q40062884-2AADC1ED-D5EB-49A4-B962-3BCBAEB63BE5Q40267502-54FAED6C-D2EC-471E-93CC-0482F0B9AC6EQ41014009-870B5F03-F78D-4DBC-9E71-B2D36947774FQ41029307-BA47442E-CFB0-4C2B-B91C-292A6C316AEDQ41078976-DDB38B7C-F7C5-4260-BD4E-33307AB10E95Q42630057-FFF7E774-4825-42B7-A3DD-9ACD583C71C7Q46158473-C732DDDD-9629-4E08-A387-99233A2A5477Q47340326-F6316776-12F0-48BA-A5AF-F72E2A395C60Q47701857-BBFF0AD4-D0F6-4CE9-BFE1-B50349D88991Q47869138-15FD3194-B1F7-480F-8CCA-43925DFAF07DQ47872616-BF359119-D674-4930-BADB-1ED62385E453Q47909842-AF5D5B72-7C40-4B41-BF12-BF4A2A91D75FQ47939060-2D45E922-71EF-4162-B3E9-D679E5F78623Q48004031-43107115-869B-418A-83CF-4B6F521443C5Q48100395-BC6372E1-DC94-400D-BB65-923469C2EE71Q48114566-0C2FDBA2-C1A2-4B96-83C6-6813B093789FQ48126556-0FD2F806-5D45-47E3-B44C-24382FD27AD7Q48177044-55CC79C3-B384-45DE-9E69-8FD7273496D0Q48177361-6AA581A0-5777-4873-881E-D7C8FBE8CA34Q48180998-06F3A31C-5C96-4A6B-8DFB-CBB6214B9104Q48359444-0AC0CB00-4287-4C01-A6B0-BBC4F05FB7D2Q48493942-6C786369-6AAF-4A2E-A6CB-02265E6472F6Q48655609-2A21C81E-FE5E-427E-9526-7A1E27F64C94Q49388858-D7C5D55B-962A-44A0-BC86-213C1F7A54DAQ55015782-BF3D0BCD-036C-4751-AB19-96888647A5FA
P2860
Macrocyclic and Other Non-Group 1 Gadolinium Contrast Agents Deposit Low Levels of Gadolinium in Brain and Bone Tissue: Preliminary Results From 9 Patients With Normal Renal Function.
description
2016 nî lūn-bûn
@nan
2016 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Macrocyclic and Other Non-Grou ...... ts With Normal Renal Function.
@ast
Macrocyclic and Other Non-Grou ...... ts With Normal Renal Function.
@en
type
label
Macrocyclic and Other Non-Grou ...... ts With Normal Renal Function.
@ast
Macrocyclic and Other Non-Grou ...... ts With Normal Renal Function.
@en
prefLabel
Macrocyclic and Other Non-Grou ...... ts With Normal Renal Function.
@ast
Macrocyclic and Other Non-Grou ...... ts With Normal Renal Function.
@en
P2093
P1476
Macrocyclic and Other Non-Grou ...... nts With Normal Renal Function
@en
P2093
Corinne Fligner
Daniel Hippe
Kenneth R Maravilla
Kiyoko Murata
Nozomu Murata
Russell Dills
P304
P356
10.1097/RLI.0000000000000252
P577
2016-07-01T00:00:00Z